Cube Biotech receives funding from Neuroallianz

30. October, 2013. Cube Biotech today joins the Neuroallianz Consortium as a new industry partner and will receive funding for the functional and structural analysis of an undisclosed human membrane protein target. The Research Center Juelich participates as academic partner in this project. Duration of the project is two years, starting in January 2014. Financial details were not disclosed. About Neuroallianz: To foster innovative research in Germany the German Federal Ministry for Education and Research (BMBF) launched an initiative titled: "BioPharma: The Strategy Competition for Future Medicines". The Neuroallianz Consortium was 1 of 3 winners of this call by BMBF and has created a novel strategic partnership concept where various academic institutions and companies are working jointly on innovative diagnostic and therapeutic research projects. The aim is to efficiently transform research into benefits for patients. Main focus areas are diagnostics and therapeutics for neurodegenerative diseases such as Parkinson's Disease, Alzheimer's Dementia, or Epilepsy. The Neuroallianz Consortium is funded by BMBF with a total budget of 40 Mio €. As of today industry partners are UCB Pharma GmbH, Life&Brain GmbH, IBL International GmbH, and Cube Biotech GmbH. Academic partners are University of Bonn, University Hospital of Bonn, LVR Clinics Essen/University of Duisburg-Essen, Fraunhofer Institute for Algorithms and Scientific Computing SCAI, and Research Center Juelich. About Cube Biotech: Cube Biotech’s mission is to provide services to the pharmaceutical community that enables the analysis of membrane protein structure and function. Cube Biotech has a well-equipped service laboratory with experienced researchers where membrane proteins are expressed, purified and crystallized. Membrane proteins are stabilized e.g. using nanodiscs and are provided for ligand binding and other biophysical and biochemical studies.